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One surface moiety that has been found to modulate activation by the alternative 
pathway is sialic acid. Activating particles such as zymosan and rabbit erythrocytes 
are relatively deficient in surface-associated sialic acid, whereas nonactivating particles 
such  as  sheep  erythrocytes  contain  an  abundance  of  sialic  acid  moieties  (1-3). 
Enzymatic removal of sialic acid residues with neuraminidase (1, 2) or conversion by 
mild oxidation with sodium periodate and reduction with borohydride to heptulosonic 
acid (1) converts the sheep erythrocyte from a nonactivating to an activating surface 
for  the  alternative  pathway.  Activation by sheep  erythrocytes requires  removal  or 
modification of at least  40%  of membrane sialic acid, and increases proportionately 
when larger amounts are affected (1).  Surface-associated sialic acid modulates alter- 
native pathway function by increasing the affinity offllH relative to B for C3b. This 
results in blocking formation of the alternative pathway C3 convertase C3bBb (1-3). 
The native  polysaccharide antigen  of type III, group B  Streptococcus  consists of a 
repeating unit of galactose, glucose, glucosamine, and a-D-N-acetylneuraminic acid in 
a  molar ratio of 2:1:1:1 (4, 5). The native antigen isolated from organisms by gentle 
extraction procedures contains one sialic  acid  residue  for each  repeating  unit,  and 
these residues completely mask all the end group galactopyranose units in the antigen 
(5). If one could extrapolate the sialic acid-rich capsule of type III from mammalian 
erythrocytes, group B streptococci might be expected to function as a  nonactivating 
surface for the alternative complement pathway. 
Several studies have failed to define a  significant role for the alternative pathway 
in  opsonophagocytosis of group B  streptococci  (6-8).  These studies  have employed 
sera with little  opsonic activity as assessed  by chemiluminescence for the test  bacte- 
rium.  A  crucial  role  for  type-specific  antibody  in  host  defense  against  group  B 
streptococcal infection has been defined (9,  10), but the role of type-specific antibody 
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in alternative pathway-mediated bactericidal activity for type III, group B Streptococcus 
has  not been investigated. Although efficient activators of the alternative pathway 
such  as  zymosan  (11)  and  rabbit  erythrocytes  (12,  13)  require  only  C3,  B,  D, 
properdin,/31H, and the C3b inactivator (C3BINA) for cleavage of C3, immunoglob- 
ulin  can  have  a  facilitatory  role  (14,  15).  For  example,  IgG  participates  in  the 
alternative pathway-mediated opsonization of Streptococcus pneumoniae  (16,  17),  Bacte- 
roides  fragilis and Bacteroides thetaiotaomicron  (18), Shigella (I 9), Pseudomonas aeurginosa (20, 
21),  group  C  meningococcus  (22),  and  some  strains  of  Staphylococcus  aureus  and 
Staphylococcus epidermidis  (23). 
These studies were designed to define the participation of the alternative comple- 
ment pathway in opsonophagocytosis of type III, group B Streptococcus and the role of 
specific antibody directed to the sialic acid-rich native capsular polysaccharide antigen 
in facilitating alternative pathway activation. 
Materials and Methods 
Bacteria.  Strain M732 of type III, group B Streptococcus, was isolated from the cerebrospinal 
fluid of a neonate with meningitis. Organisms were stored at -70°C in 0.5-ml aliquots of Todd- 
Hewitt Broth (THB) 1 (Difco Laboratories, Detroit, Mich.). Frozen organisms were thawed and 
streaked onto a blood-agar plate and incubated overnight at 37°C. Two loopfuls of plate-grown 
organisms were  inoculated into 250  ml nephelometry flasks containing 30  ml of THB and 
grown at 37°C for ~2 h to an OD of 0.1  (starting OD -- .02) at 650 nm as determined by a 
Coleman Junior Spectrophotometer  (model 6C,  Coleman Systems,  Irvine, Calif.).  Cultures 
grown in this manner are in early log-phase growth (24). 30 ml of broth culture was centrifuged 
at 5,000 rpm for 10 min, and the pellet was resuspended in 16 ml of minimal essential medium 
(MEM) with Earle's balanced salt solution (Microbiological Associates,  Walkersville, Md.). A 
final  1/10 dilution of the bacterial suspension in MEM  was  required to achieve a  ratio of 
bacteria:leukocytes (WBC) of ~3-4:1 in the opsonic reaction mixture. 
Neurarninidase-treated Bacteria.  Enzymatic remov~/l of sialic acid residues was  accomplished 
by incubating  plate-grown organisms in glucose-enriched, non-pH-titrated  THB (25) containing 
0.43  U/ml of Clostridium perfringens neuraminidase (type V, lot  118 C-8020;  Sigma Chemical 
Co., St. Louis, Mo.). 1 U of C. perfringens neuraminidase liberates 1 #mol of N-acetyl neuraminic 
acid per min from N-acetyl neuramin-lactose at  pH  5.0 at  37°C. The growth  medium was 
supplemented once during an incubation period of -3 h with neuraminidase (0.43 U/ml THB) 
and organisms were harvested when the pH reached 5.0. Cultures grown in this manner are in 
mid-log-phase growth (24, 25). After washing in THB, the pellet was resuspended to an OD of 
0.1 at 650 nm and diluted as described for the opsonic assay. Control organisms were incubated 
in the same manner in glucose-enriched THB titrated using 1 N NaOH to maintain the pH at 
7.0-7.5. 
Preparation of Rabbit Antisera.  New Zealand White rabbits were  immunized with formalin- 
killed type III, group B streptococci grown in pH-titrated THB according to the method of 
McCarty and Lancefield (26). Hyperimmune rabbit antiserum to Streptococcus pneumoniae type 
14 was prepared in the same manner. 
Human Sera.  Aliquots of human sera were  frozen at -70°C within 1 h  after collection to 
preserve complement activity. Genetically  C2-deficient (C2D) human serum was obtained from 
a  woman with inactive systemic lupus erythematosis who  had  normal levels of C3,  B, C3- 
inactivator, and/31H (27). Agammaglobulinemic  serum was obtained from a child with severe 
combined immunodeficiency (IgG:  14 mg/100 ml, IgA and IgM: undetectable) and normal 
complement levels  except  for  Clq  which  was  30%  of the  normal serum  pool  value  (28). 
1Abbreviations used in this paper: BSA, bovine serum albumin;  C3BINA, C3B  inactivator; C2D, C2 
deficient; CFU, colony-forming units; GVB, isotonic, pH  7.5, veronal-NaCl buffer that  contained 0.1% 
gelatin; GVB  ++, GVB with 0.15 mM Ca  ++ and 0.5 mM  Mg÷+; MEM,  minimum essential medium; 
MgEGTA, GVB supplemented to 4 mM Mg  ÷+ and 16 mM EGTA and adjusted to pH 7.5; THB, Todd- 
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Complement activity in selected sera was inactivated by heating to 56°C for 30 min. Concen- 
trations of type III, group B streptococcal antibody were determined with a radioactive antigen- 
binding  assay  described  previously  (10).  The  sera  used  as  sources  of antibody  contained 
concentrations  of antibody  directed  against  the  capsular  polysaccharide  antigen  of the  test 
bacterium  that  are  representative  of  the  natural  range  found  in  normal  adults.  In  this 
opsonophagocytic assay,  >90%  reduction  in colony-forming units  (CFU)  has been  uniformly 
observed with adult  sera that  contained >2 ~g/ml of type-specific antibody.  The majority of 
adult sera that contained <2/~g/ml of antibody have failed to kill 90% of the initial inoculum 
(29). 
Buffers.  Isotonic, pH 7.5,  veronal-NaC1 buffer, that contained 0.1% gelatin (GVB) made to 
0.15 mM Ca  ++ and 0.5 mM Mg  ++ (GVB ++) was prepared as described (30).  MgEGTA buffer 
was made by supplementing  GVB to 4  mM Mg  ÷+, and  16 mM EGTA and adjusting to pH 
7.5.  Dilution  of serum  1/2  with  MgEGTA  to  chelate  calcium  permitted  C3  activation  by 
zymosan  (85%  consumption), but not by antibody-coated sheep erythrocytes. 
Complement Components.  Functionally purified guinea pig C2 was prepared by the method of 
Borsos et al. (31). 
Preparation of Leukocyte Suspension.  20  ml  of peripheral  venous  blood  was  collected  from 
normal volunteers in a nonheparinized plastic syringe. 3-ml aliquots of blood were added to 12- 
×  75-mm polypropylene tubes (Fisher Scientific Co., Pittsburgh,  Pa.) each containing 1 ml 6% 
dextran  (Dextran T70, Pharmacia Fine Chemicals, Div. of Pharmacia, Inc., Piscataway, N. J.) 
and 0.75 ml citrate solution (16 g citric acid and 50 g sodium citrate per liter). The erythrocytes 
were  sedimented  at  37°C  for 45  min.  The  WBC-rich  plasma  supernate  was  separated  and 
washed  twice in MEM with  1% bovine serum albumin  (BSA),  (Armour Pharmaceutical  Co., 
Chicago,  Ill.)  before  and  after  lysis  of contaminating  erythrocytes  with  0.84%  ammonium 
chloride. The WBC were resuspended  in MEM with  1% BSA at  1 ×  107 WBC/ml. 
Opsonophagocytic Assay.  A  modification  of the opsonophagocytic  assay  of Baltimore et  al. 
(24)  was employed.  12-  ×  75-mm polypropylene tubes contained a  total reaction mixture vol 
of 0.4 ml that consisted of 0.1  ml WBC suspension (-1 ×  106 WBC), 0.1 ml bacterial suspension 
(~3  ×  106 CFU), 0.1  ml  of serum  as  an  antibody  source  and  0.1  ml  of fresh  serum.  When 
exogenous  complement  was  not  employed,  0.1  ml  of MEM  was  substituted.  Control  tubes 
lacking either WBC, or test serum, or complement were included  in each experiment. Tubes 
were incubated for 40 min at 37°C with end-over-end rotation in a Fisher Roto-Rack apparatus. 
Pre- and postincubation  specimens (95 #1)  were removed and WBC lysed in sterile distilled 
water (1/10 dilution).  Four additional  1/10 dilutions in 0.15  M  NaCI were prepared.  A  10-/~1 
specimen from each of the four final dilutions was streaked on a  blood-agar plate which was 
incubated overnight at 37°C. Colonies were counted using a Quebec Colony Counter (American 
Optical Corp., Scientific Instrument Div., Buffalo, N. Y.). Results were expressed as the percent 
decrease of the initial number of viable bacteria as: 
100 -- [CFU at 40 min X  100]. 
LEV6  a?b-m-=Jn  3 
Results represent the mean of a  minimum of two determinations. 
When  the classical pathway  was  inhibited  by  MgEGTA, the experimental  procedure was 
modified to include a  preopsonization step to avoid toxicity to the WBC. Sera diluted  1/2 in 
MgEGTA or GVB  +* as a control were incubated 5 min at 37°C to allow the EGTA to chelate 
the available calcium. After the addition of bacteria (0.1  ml of 3 ×  107 CFU/ml) the mixtures 
were opsonized for 30 min at 37°C with end-over-end rotation, and then chilled and centrifuged. 
The bacteria were washed once in MEM and then resuspended in MEM with or without added 
WBC for continuation of the phagocytic-killing assay as defined above. 
Absorption of Sera.  2-ml  aliquots  of heat-inactivated  sera  were absorbed  using  a  pellet of 
washed, whole, early-log-phase type III, group B streptococci or purified type III native capsular 
polysaccharide antigen  (4)  coupled to sheep erythrocytes by a  modification of the method of 
Baker et al. (32).  An absorption control employing purified type 3 pneumococcal polysaccharide 
antigen  (kindly provided by Dr. Richard  Markham)  was processed in the same manner.  1-ml 
suspensions  of 0.15  M  NaCI  that  contained  2.0  mg of native type III, group  B  streptococcal 
polysaccharide  or  500  /~g of type  3  pneumococcal  antigen  were  added  to  0.5-ml  pellets  of 1278  ANTIBODY-MEDIATED  ALTERNATIVE PATHWAY  ACTIVATION 
TABLE  I 
Demonstration of Alternative Pathway-mediated Bactericidal Activity for Type III, Group B Streptococcus 
in Serum that Contained Specific Antibody in Sufficient Concentration 
Type III-specific 
antibody concen- 
tration of normal 
human serum 
used in reaction 
mixture 
Complement source 
Bactericidal index* 
Mean~:  Range  SD 
p.g/ml 
2.8  Autologous 
0.7  Autologous 
2.8  .None 
0.7  None 
2.8§  C2D 
0.7§  C2D 
0.4  C2D 
98  97-98  0.6 
82  69-94  8.2 
0  -  0 
0  -  0 
96  94-98  1.3 
6  0-12  5.1 
34  20-46  8.6 
100  [CFU at 40 rain ×100].  * Bactericidal index =  -  I_'~'U at"~ m~n 
:~ Results represent the mean of four experiments. 
§ Heat-inactivated  at 56°C for 30 min. 
packed, washed sheep erythrocytes. Preliminary studies had shown these concentrations were 
optimal for sensitization of the sheep erythrocytes with each of these antigens.  1 ml of 0.1% 
chromium chloride (CrCIa • 6 H20) was added and the mixture allowed to stand at 25°C for 
5 min. After washing the antigen-sensitized sheep erythrocytes with 0.15 M  NaCI, 2 ml of heat- 
inactivated serum was added to each pellet and incubated with shaking for 1 h at 37°C and  1 
h  at  4°C.  After centrifugation  at  5,000  rpm  for  15  min,  the  absorbed  sera  were  filtered, 
aliquoted and stored at -70°C until tested. 
Results 
Sera containing endogenous complement and moderate (2.8 ~g/ml) or low (0.7 pg/ 
ml)  concentrations  of antibody killed 98  and  82%  of the  initial bacterial inoculum 
after a  40-min incubation period (Table I). These values are representative for adult 
sera previously tested in this system. Heat-inactivated serum  failed to opsonize type 
III,  group  B  streptococci  despite  moderate  levels  of  antibody.  C2D  serum  that 
contained low levels of type-specific antibody (0.4 pg/ml) could restore the ability of 
heated serum that contained 2.8/~g/ml of type-specific antibody to kill these organisms 
(96% decrease in CFU). C2D serum was not effective in restoring the killing ability of 
heated serum that contained 0.7/~g/ml antibody (6% decrease in CFU). Reconstitu- 
tion  of C2D  serum  with  40  U  of functionally purified  guinea  pig C2  restored  the 
bactericidal capacity of C2D serum to 87% reduction in CFU, a  level similar to that 
of normal,  antibody-deficient serum.  Guinea  pig,  rather  than  human  C2  was  em- 
ployed,  because  factor  B  may  be  a  contaminant  of  partially  purified  C2,  and 
heterologous combinations of B are incompatible (33). These results indicate that the 
killing ability of serum that contained low levels of antibody depends on activation of 
the classical complement pathway, but with higher levels of antibody, the alternative 
pathway can be recruited even in the absence of an intact classical pathway. 
It was possible that  the concentration of antibody was critical in this assay either 
because of its role in the fixation of complement or because of its interaction with the 
Fc  receptors  of  the  phagocytic  cells.  The  following  experiment  was  designed  to M.  EDWARDS, A.  NICHOLSON-WELLER, C.  BAKER, AND  D.  KASPER  1279 
TABLE II 
Mechanism of Alternative Pathway-mediated Opsonophagocytosis of Type III, Group 
B Streptococcus 
Concentration of 
type III group B 
Type III, group B  streptococcal anti-  Bactericidal 
streptococcal anti-  Complement source  body added after  index* 
body concentration  opsonization pro- 
cedure 
Itglml  Izg/ml 
2.8  Autologous  2.8  92 
0.7  Autologous  2.8  77 
2.8  None  2.8  0 
0.7  None  2.8  0 
2.8~:  C2D  2.8  94 
0.7~:  C2D  2.8  3 
0.4  C2D  2.8  0 
.CFU at 40 rain  ] 
* Bactericidal index =  100 -  L CFU at 0 min  ×100  . 
:~ Heat-inactivated at 56°C for 30 min. 
distinguish  between  these two alternatives.  Bacteria were incubated  for 30 min with 
C2D serum  and  heated  serum  that  contained  antibody in  moderate  (2.8 #g/ml)  or 
low (0.7/zg/ml) concentrations and then washed in buffer. More type-specific antibody 
(2.8  /zg/ml)  as  contained  in  heated  serum  was  added  to  the  washed  bacteria  and 
finally WBC were added for continuation of the killing assay. The addition  of more 
antibody to bacteria after complement was fixed failed to influence the opsonophag- 
ocytic assay (Table II). Therefore, the significance of the critical antibody concentra- 
tion  is  in  mediating  complement  activation  and  not  in  interacting  with  the  Fc 
receptors on the phagocytic cells. 
Inhibition  of the  classical  pathway  by  diluting  serum  1/2  in  MgEGTA  buffer 
during the opsonization step caused no reduction in subsequent phagocytic killing for 
five sera  containing  a  range  from  moderate  to  high  concentrations  of type-specific 
antibody  (Table  III).  However,  significant  inhibition  of opsonophagocytosis  was 
observed when the classical complement pathway was inhibited by MgEGTA for five 
sera containing antibody  in  very low concentrations  (t  =  8.0,  P  <  0.005).  Bacterial 
growth  was  observed  in  reaction  mixtures  containing  MgEGTA  or GVB  +÷  in  the 
absence of serum. 
When bacteria were opsonized for 30 min in sera diluted  I/2 in GVB  ++ before the 
addition  of WBC,  both  low  and  moderate  to  high  concentrations  of type-specific 
antibody  permitted  a  large  reduction  in  CFU.  Bacteria  that  have  been  opsonized 
before incubation  with WBC  (Table  III) are apparently  more readily phagocytized 
than bacteria simultaneously incubated with serum and WBC (Table I). This increase 
in killing may be the result of anti-complementary effects of the leukocyte preparation 
such as nonspecific activation of complement in the fluid phase or the degradation of 
surface deposited C3b by released proteolytic enzymes from the leukocytes. 
The role of antibody to the native capsular polysaccharide antigen  in facilitating 
alternative  complement  pathway-mediated  opsonophagocytosis of type III, group B 
streptococci was further  defined  through absorption  of sera with type III organisms 
and  purified  type III native  capsular  antigen  (4)  (Table  IV).  The  initial  antibody 1280  ANTIBODY-MEDIATED  ALTERNATIVE  PATHWAY  ACTIVATION 
TABLE  III 
Antibody Facilitation of Alternative Pathway-mediated Opsonophagocytosis of Type III, Group B 
Streptococcus 
Type III, group B  Bactericidal 
streptococcal antibody  index* 
Serum source  concentration  Buffer 
Mean  Range  Mean  Range 
Five antibody-deficient sera  0.3 
Five antibody-deficient sera  0.3 
Five sera that contained antibody  14.9 
in  moderate  to  high concentra- 
tions 
Five sera that contained antibody  14.9 
in  moderate  to  high concentra- 
tions 
~g/ml 
--  GVB  ++  93:~  85-96 
--  MgEGTA  40:~  9-54 
(2.8-40.2)  GVB  ++  97  96-98 
(2.8-40.2)  MgEGTA  97  95-98 
[CFU at 4__0 min  ] 
* Bactericidal index =  100 -  [_ CFU at 0 min  Xl00  . 
Difference between  bactericidal  index of antibody-deficient sera  in  GVB  ++  vs.  MgEGTA  buffers  is 
significant by paired t test (t =  8.0, P <  0.005). 
TABLE  IV 
Role of Antibody to the Native Capsular Polysaccharide Antigen in Alternative Pathway-mediated 
Opsonophagocytosis of Type III, Group B Streptococcus 
Final type 
III GBS  Bacteri- 
Serum  Absorption  antibody  Complement  cidal 
concentra-  index* 
tion 
#g/ml 
NHSI:[:  None  2.8  Autologous  98 
ANHSI§  None  2.8  None  0 
ANHSI  None  2.8  C2D  90 
ANHS1  Type III GBS cells  0.3  None  0 
ANHSI  Type III GBS polysaccharide  0.4  None  0 
ANHS~  Type III GBS cells  0,3  C2D  0 
ANHS~  Type III GBS polysaccharide  0.4  C2D  39 
ANHS1  Type 3 pneumococcal polysaccharide  2.8  C2D  95 
C2D  None  0.4  Autologous  29 
[CFU at 40 min  ] 
* Bactericidal index =  100 -  L CFU at 0 min  ×100  . 
NHSI, Serum from normal donor containing the antibody concentration specified. 
§ ANHS~, Normal human serum that was heat-inactivated at 56°C for 30 min. 
concentration  of 2.8/xg/ml  was  reduced  to 0.3  and  0.4/~g/ml  after  absorption  with 
whole organisms  and  native type III polysaccharide  antigen, respectively.  No  reduc- 
tion  in  serum  antibody  concentration  occurred  after  absorption  with  type  3  pneu- 
mococcal  polysaccharide  antigen.  Addition  of C2D  serum  as  a  complement  source 
did not restore opsonophagocytic  activity to serum that had been absorbed with either 
whole bacteria or purified type III capsular polysaccharide  antigen to remove specific 
antibody.  Opsonization  was unaffected when  specific antibody-containing  serum was M.  EDWARDS, A.  NICHOLSON-WELLER, C.  BAKER, AND D.  KASPER  1281 
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FIG.  1.  Slide  agglutination reaction graded 4+  (large clumps, clear background), 3+ (large and 
small clumps,  clear background), 2+ (small  clumps, milky background), 1  + (fine  granularity against 
a milky background) and negative for: (--) neuramirfidase-treated  organisms with antiserum to S. 
pneumoniae, type 14;  (-.-) pH-titrated organisms with antiserum to S. pneumoniae, type 14;  (---) 
neuraminidase-treated organisms  with antiserum to native type III, group B Streptococcus; (  .... ) pH- 
titrated organisms with antiserum to native type III, group B Streptococcus. 
preabsorbed with  type 3 pneumococcal polysaccharide antigen  and then combined 
with C2D serum as a complement source. These results indicate that sufficient specific 
antibody directed against the native type III capsular polysaccharide antigen  facili- 
tates opsonophagocytosis of type III, group B Streptococcus  via the alternative comple- 
ment pathway. 
The contribution of terminal sialic acid residues in the type III, group B strepto- 
coccal capsule to inhibition of alternative pathway-mediated opsonophagocytosis by 
sera deficient in type-specific antibody was determined by experiments in which the 
immunologic specificity of the organisms was modified by neuraminidase cleavage of 
the terminal sialyl residues. Removal of the sialic acid results in an antigen identical 
to the capsular polysaccharide of S. pneumoniae,  type 14  (5,  34).  Organisms grown in 
the  presence  of C.  perfringens  neuraminidase  in  an  acidic  medium  exhibited  strong 
agglutination  reactions with antiserum to S. pneumoniae,  type 14 and weaker aggluti- 
nation reactions with antiserum to the native type III, group B streptococcal antigen, 
prepared using organisms grown at neutral pH to prevent cleavage of the acid-labile 
sialic acid end-groups (4,  34)  (Fig.  1). Control non-neuraminidase-treated  organisms 
grown  in  broth  titrated  to  maintain  a  neutral  pH  exhibited  strong  agglutination 
reactions  with  antiserum  to  the  native  antigen  and  agglutinated  minimally  with 
antiserum to S. pneumoniae,  type 14. 
The  inhibition  of bactericidal  activity  previously  observed  when  sera  with  low 
concentrations  of type-specific  antibody  were  opsonized  in  MgEGTA  buffer  was 
overcome  when  neuraminidase-cleaved  organisms  were  added  to  the  subsequent 
phagocytic mixture (Fig. 2). The alternative pathway-mediated bactericidal capacity 
of antibody-deficient  sera for the partially desialated  type III, group B  streptococci 
was equal to that of sera that contained specific antibody in higher concentrations. 
Because cleavage of all terminal sialic acid residues yields an incomplete type III 1282  ANTIBODY-MEDIATED ALTERNATIVE PATHWAY ACTIVATION 
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Fia.  2.  Bactericidal  index for alternative pathway-mediated  opsonophagocytosis  of type III, group 
B streptococci  grown in pH-titrated media (C) or in the presence of neuraminidase (N) by sera that 
contained high or low concentrations of type-specific antibody. Mean and range in bactericidal 
indices are indicated for four sera. 
capsular antigen which is structurally identical to the S. pneumoniae, type  14 polysac- 
charide  antigen  (5,  34),  it  was  possible  that  antibody  directed  to  the  partially 
unmasked  galactopyranose residue  was  mediating opsonophagocytosis of the  enzy- 
matically modified bacteria. Agammaglobulinemic serum was employed to determine 
whether  bactericidal  activity for the  cleaved organisms was mediated  by antibody 
directed to an immunodeterminant exposed by neuraminidase treatment or if partial 
desialation had converted the enzyme-treated organisms into non-antibody-dependent 
activating particles  for the  alternative  pathway.  Agammaglobulinemic serum  con- 
tained  no  detectable  antibody to  the  S. pneumoniae, type  14  or the  native  type III, 
group  B  streptococcal  antigens.  97%  reduction  in  the  inoculum  of neuraminidase- 
treated  bacteria occurred  in  MgEGTA  buffer, whereas  no  killing  of fully sialated 
organisms was observed in  this buffer system. These results demonstrate that  alter- 
native pathway-mediated bactericidal activity for partially desialated type III, group 
B streptococci is not antibody dependent. 
Discussion 
The preceding experiments show that complement is required for the opsonophag- 
ocytosis of type  III, group  B  Streptococcus. The  effect  of a  critical  concentration  of 
antibody  in  promoting  opsonophagocytosis was  mediated  by complement  fixation 
and not by interaction of antibody with neutrophil  Fc receptors because additional 
antibody after complement was fixed failed to influence opsonophagocytosis (Table 
II). Low levels of antibody utilize the classical pathway, but higher levels of specific 
antibody,  in  the range correlated with  in  vivo protection  in  infants  (9),  recruit  the 
alternative  pathway.  Three  possible  mechanisms  may be involved  in  antibody-de- 
pendent activation of the alternative pathway. 
First,  the  role of immunoglobulin  in  the  recruitment  of the  alternative  pathway 
might depend on deposition of C3b  (35,  36)  by the classic complement pathway  142 
convertase. C3b, the major cleavage fragment of (]3, participates in the assembly of 
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demonstrate that the classic pathway is not needed to recruit the alternative pathway 
for opsonization of group B streptococci when there is sufficient antibody. 
Secondly, May and Frank (38, 39) described a C 1-bypass mechanism of  complement 
activation. The pathway depends on high concentrations of specific antibody, C 1 and 
B  for activation of C3. In our experiments, MgEGTA was used to dilute serum for 
chelation of Ca  ++  and  inactivation of C1. The results show that  MgEGTA-diluted 
serum was comparable to normal serum and C2D serum in supplying a complement 
source. These results  rule out  a  critical  role for the C1  bypass  mechanism  for the 
antibody-dependent activation of the alternative pathway for opsonization of group 
B streptococci. 
Finally,  the  surface  of an  alternative  pathway  activator must  capture  the  C3b 
generated by the Mg÷+-dependent fluid-phase C3 convertase formed by the interac- 
tion of native C3, B, properdin, and I) in the presence of~lH  and C3bINA (11-13). 
The enzymatic activity of this convertase is held in check by/~IH which accelerates 
the intrinsic decay of C3bBb  (40, 41)  and augments the activity of the C3bINA in 
irreversibly  destroying  the  binding  site  for  B  (42).  Sialic  acid  is  one  membrane 
constituent  that  has  been shown  to modulate surface activation of the  alternative 
pathway (1, 2). Surfaces of activating particles for the alternative pathway have little 
sialic acid, whereas nonactivating surfaces are relatively rich in sialic acid. Surface- 
associated sialic acid greatly increases the binding affinity of/~IH for C3b, thereby 
accelerating intrinsic decay of the convertase, whereas the decreased affinity of i~lH 
for the surface of an activating particle favors formation of the convertase on bound 
C3b (1-3). 
The native polysaccharide antigen  of type III,  group  B  Streptococcus contains  an 
abundance  of sialic  acid  residues  that  are  all  present  as  endgroups,  completely 
masking the peripheral galactopyranosyl residues of the repeating unit of the antigen 
(5,  34).  Our  experiments  indicate  that  this  particle  functions  as  a  nonactivating 
surface  for  the  alternative  pathway  in  sera  that  contained  low  concentrations  of 
specific antibody.  However, in  the presence of a  critical concentration of antibody 
with specificity for the sialic acid-containing immunodeterminant, alternative path- 
way activation occurs. The specificity of this antibody requirement was demonstrated 
by the complete inhibition of alternative pathway-mediated opsonization after ab- 
sorption of serum that contained 2.8 #g/ml of type-specific antibody with either whole 
type III organisms or native type III capsular polysaccharide. 
The role of terminal sialyl residues in creating an antibody-dependent requirement 
for  activation  of the  alternative  pathway  was  then  explored.  Because  enzymatic 
removal of sialic acid residues on sheep erythrocytes will convert this particle from a 
nonactivating to an activating surface for the alternative pathway (1), type III, group 
B streptococcal terminal sialic acid residues were enzymatically cleaved to examine 
the effect that altering this surface moiety would have on the requirement for specific 
antibody. Bacteria grown in the presence of neuraminidase exhibited reduced agglu- 
tination  with  antibody  to  the  native  capsular  antigen  but  reacted  strongly  with 
antibody to S. pneumoniae, type  14.  Because the nonsialated core antigen of type III, 
group B Streptococcus is structurally identical to the S. pneumoniae, type  14 antigen (5, 
34), these serologic reactions indicated that neuraminidase had cleaved a  portion of 
the terminal sialic acid residues. Antibody-deficient sera exhibited alternative path- 
way-mediated bactericidal  activity for the  partially  desialated  organisms  that  was 1284  ANTIBODY-MEDIATED ALTERNATIVE  PATHWAY  ACTIVATION 
equal to that observed in sera with antibody concentrations sufficient for alternative 
pathway  activation.  This  ruled  out  the  possibility  that  antibody  directed  against 
unmasked  galactopyranose residues  was  mediating alternative pathway activation. 
Therefore, once sialic acid is removed antibody is no longer required for activation of 
this pathway. 
These experiments do not elucidate the mechanism by which antibody directed at 
an immunodeterminant that contains a terminal sialic acid residue permits alternative 
pathway activation. One possibility is  that  the antibody binds  and  neutralizes the 
sialic acid residues resulting in impaired fllH binding to C3b, which would allow the 
formation of a deregulated C3bBb convertase (1). Alternatively, carbohydrate groups 
on  the  immunoglobulin  might  provide a  protected site  for C3b  deposition  that  is 
topically removed from the bacterial capsular sialic acid residues. 
A receptor for activators of the alternative pathway that permits ingestion in the 
absence of exogenous proteins has been demonstrated for human  blood monocytes 
(43, 44). The possibility that specific antibody or neuraminidase cleavage created an 
activating  particle  that  could  be  directly  ingested  by  monocytes  in  the  opsonic 
reaction mixture was  ruled out  by including  a  serum-free control in each opsono- 
phagocytosis  test.  Because  bacterial  growth  was  always  observed,  these  findings 
confirmed  the  complement  dependence  of  bactericidal  activity  and  excluded  a 
significant  role  for  leukocyte-mediated  opsonization  in  the  absence  of exogenous 
proteins in this assay system. 
These experiments have shown  an essential  role for complement in  this opsono- 
phagocytosis  assay.  The  essential  ligand  is  presumably  C3b  which  is  the  most 
important opsonic ligand generated during complement activation (45).  Potentially, 
fixation of C3b by the alternative pathway is a  major factor in natural host defense 
because activation by this pathway can occur in  the  absence of antibody  (11-13), 
whereas activation of the classical  complement pathway requires specific antibody 
(46).  Our experiments show that  it  is sialic acid residues on the type III,  group  B 
streptococcal capsule  that  allow  this  pathogen  to  evade  this  natural  host-defense 
mechanism.  Only  the  presence  of specific  anti-capsular  antibody,  i.e.,  acquired 
immunity, will permit alternative complement pathway activation by the organism 
in its fully sialated state. 
It is of interest that several virulent bacteria other than group B Streptococcus  have 
sialic acid residues in their capsules. The type III, group B Streptococcus  presents itself 
to the host as a  fully sialated surface as do serogroups B and C  Neisseria meningitidis 
and K1 Escherichia coli  (47, 48). Interestingly, less-pathogenic serogroups of meningo- 
cocci and E.  coli  that  have some sialic acid in their capsules have this present  in  a 
repeating unit, but it is not the exclusive terminal sugar. 
Summary 
The native capsular polysaccharide antigen of type III, group B Streptococcus contains 
a  terminal  sialic  acid  residue  on  each  repeating  unit  that  masks  all  end-group 
galactopyranose residues and prevents alternative pathway complement activation by 
adult  human  sera in  the absence of type-specific antibody. The critical role of the 
sialic  acid  residues  in  allowing  the  organism  to  evade  activating  the  alternative 
complement  pathway was  shown  when  neuraminidase  treatment  of the  organism 
converted the bacteria to activators of the alternative pathway as assessed in again- M.  EDWARDS, A.  NICHOLSON-WELLER, C.  BAKER, AND  D.  KASPER  1285 
maglobulinemic serum. The requirement  for specific antibody in permitting alterna- 
tive  pathway  activation  by  the  fully  sialated  bacteria  was  shown  when  sera  that 
contained  low levels of specific antibody failed  to activate this  pathway,  and when 
prior absorption of serum that contained higher type-specific antibody levels with the 
capsular antigen failed to activate this pathway. The use of C2-deficient sera showed 
that  the  classical  pathway  was  not  required  for  antibody-dependent  alternative 
pathway activation.  The use of isotonic, pH 7.5, veronal-NaCl buffer that contained 
1%  gelatin  and  that  was  supplemented  to  4  mM  Mg  ++  and  16  mM  EGTA  and 
adjusted to pH 7.5 (MgEGTA) ruled out the participation of the C 1-bypass pathway. 
The  presence  of sialic  acid  on  the  bacterial  surface  is  one  means  of evading  an 
important mechanism of natural immunity, namely activation of complement by the 
alternative  pathway.  Only specific antibody,  i.e.,  acquired  immunity, can overcome 
this virulence factor. 
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